EPISODE · Feb 28, 2012 · 10 MIN
Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities
from Journal of Clinical Oncology (JCO) Podcast
Patients with epidermal growth factor receptor (EGFR) gene mutations should receive EGFR tyrosine kinase inhibitors as 1st line therapy because they produce higher response rates, long progression free survival, reduced toxicity, improved symptom control and convenience of oral administration compared to chemotherapy doublets.
NOW PLAYING
Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m